CMS’s proposal for near-flat Medicare Advantage reimbursements paired with a rising medical care ratio has turned what was once a dependable profit engine for U.S. health insurers into a source of real uncertainty.
At the same time, new independent studies strongly suggest that Medicare Advantage still delivers greater value than traditional Medicare, with lower average costs to the federal government plus meaningfully reduced out-of-pocket expenses and richer benefits for enrollees. That split between tighter policy pressure and clear evidence of program value is reshaping how the market views every company closely tied to this business.
